disease-modifying therapies

R&D

The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.